Abstract:Metformin is the most commonly prescribed medication for type 2 diabetes, owing to its glucose-lowering effects, which are mediated through the suppression of hepatic glucose production (reviewed in refs. <a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="/articles/s42255-019-0146-4#ref-CR3">3</a>). However, in addition to its effects on the liver, metformin reduces appetite and in preclinical models exerts beneficial effects on ageing and a number of diverse diseases (for example, cognitive disorders, cancer, cardiovascular disease) through mechanisms that are not fully understood<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="/articles/s42255-019-0146-4#ref-CR3">3</a>. Given the high concentration of metformin in the liver and its many beneficial effects beyond glycemic control, we reasoned that metformin may increase the secretion of a hepatocyte-derived endocrine factor that communicates with the central nervous system<a href="/articles/s42255-019-0146-4#ref-CR4">4</a>. Here we show, using unbiased transcriptomics of mouse hepatocytes and analysis of proteins in human serum, that metformin induces expression and secretion of growth differentiating factor 15 (GDF15). In primary mouse hepatocytes, metformin stimulates the secretion of GDF15 by increasing the expression of activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP; also known as DDIT3). In wild-type mice fed a high-fat diet, oral administration of metformin increases serum GDF15 and reduces food intake, body mass, fasting insulin and glucose intolerance; these effects are eliminated in GDF15 null mice. An increase in serum GDF15 is also associated with weight loss in patients with type 2 diabetes who take metformin. Although further studies will be required to determine the tissue source(s) of GDF15 produced in response to metformin in vivo, our data indicate that the therapeutic benefits of metformin on appetite, body mass and serum insulin depend on GDF15.

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease

GDF15 is required for maintaining subcutaneous adipose tissue lipid metabolic signature

GDF15 promotes weight loss by enhancing energy expenditure in muscle

GDF15 increases insulin action in the liver and adipose tissue via a β-adrenergic receptor-mediated mechanism

Comprehensive Role of GDF15 in Inhibiting Adipogenesis and Hyperlipidemia, Enhancing Cardiovascular Health and Alleviating Inflammation in Metabolic Disorders

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Body weight regulation via MT1-MMP-mediated cleavage of GFRAL

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation

GDF15 deficiency promotes high fat diet-induced obesity in mice

Hepatocyte-derived GDF15 suppresses feeding and improves insulin sensitivity in obese mice

Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous GDF15

GDF15 is dispensable for the insulin-sensitizing effects of chronic exercise

GFRAL Is Widely Distributed in the Brain and Peripheral Tissues of Mice

Adaptive thermogenesis is mediated by GDF15 via the GFRAL neuronal axis in mice

Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH

GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin

Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

Saturated Fatty Acids Promote GDF15 Expression in Human Macrophages through the PERK/eIF2/CHOP Signaling Pathway

Identification and characterization of human GDF15 knockouts